TenNor Therapeutics Keeps Share Capital Steady at 52.33 Million H Shares in September 2026

Bulletin Express

Oct 02

TenNor Therapeutics (Suzhou) Limited (stock short name: TENNOR THERAP-B) has reported no changes to its share capital structure for the month ended 30 September 2026, according to the Monthly Return for Equity Issuer filed with Hong Kong Exchanges and Clearing Limited on 2 October 2026.

The company’s issued share capital remained at 52.33 million ordinary H shares with a par value of RMB 1.00 each, translating into issued share capital of RMB 52.33 million. No shares were issued, repurchased, or cancelled during the period, and the number of treasury shares stood at zero.

TenNor confirmed that it continues to meet the Hong Kong Main Board’s minimum public-float requirement of 25 percent of issued shares. The filing also shows no outstanding share option schemes, warrants, convertible securities, or other equity-linked instruments that could dilute current shareholders.

The return was submitted by Chairman and CEO Ma Zhenkun, reaffirming the stability of the biopharmaceutical company’s capital base heading into the final quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1108503640"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108503640\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108503640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-02 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108503640","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics Keeps Share Capital Steady at 52.33 Million H Shares in September 2026","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited (stock short name: TENNOR THERAP-B) has reported no changes to its share capital structure for the month ended 30 September 2026, according to the Monthly Return for Equity Issuer filed with Hong Kong Exchanges and Clearing Limited on 2 October 2026.</p>\n<p>The company’s issued share capital remained at 52.33 million ordinary H shares with a par value of RMB 1.00 each, translating into issued share capital of RMB 52.33 million. No shares were issued, repurchased, or cancelled during the period, and the number of treasury shares stood at zero.</p>\n<p>TenNor confirmed that it continues to meet the Hong Kong Main Board’s minimum public-float requirement of 25 percent of issued shares. The filing also shows no outstanding share option schemes, warrants, convertible securities, or other equity-linked instruments that could dilute current shareholders.</p>\n<p>The return was submitted by Chairman and CEO Ma Zhenkun, reaffirming the stability of the biopharmaceutical company’s capital base heading into the final quarter of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics Keeps Share Capital Steady at 52.33 Million H Shares in September 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics Keeps Share Capital Steady at 52.33 Million H Shares in September 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-02 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited (stock short name: TENNOR THERAP-B) has reported no changes to its share capital structure for the month ended 30 September 2026, according to the Monthly Return for Equity Issuer filed with Hong Kong Exchanges and Clearing Limited on 2 October 2026.</p>\n<p>The company’s issued share capital remained at 52.33 million ordinary H shares with a par value of RMB 1.00 each, translating into issued share capital of RMB 52.33 million. No shares were issued, repurchased, or cancelled during the period, and the number of treasury shares stood at zero.</p>\n<p>TenNor confirmed that it continues to meet the Hong Kong Main Board’s minimum public-float requirement of 25 percent of issued shares. The filing also shows no outstanding share option schemes, warrants, convertible securities, or other equity-linked instruments that could dilute current shareholders.</p>\n<p>The return was submitted by Chairman and CEO Ma Zhenkun, reaffirming the stability of the biopharmaceutical company’s capital base heading into the final quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1108503640","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108503640","pubTimestamp":1790946114,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited (stock short name: TENNOR THERAP-B) has reported no changes to its share capital structure for the month ended 30 September 2026, according to the Monthly Return...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics 2026年9月股本稳定在5,233万股H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited (stock short name: TENNOR THERAP-B) has reported no changes to its share capital structure for the month ended 30 September 2026, according to the Monthly Return for Equity Issuer filed with Hong Kong Exchanges and Clearing Limited on 2 October 2026.\nThe company’s issued share capital remained at 52.33 million ordinary H shares with a par value of RMB 1.00 each, translating into issued share capital of RMB 52.33 million. No shares were issued, repurchased, or cancelled during the period, and the number of treasury shares stood at zero.\nTenNor confirmed that it continues to meet the Hong Kong Main Board’s minimum public-float requirement of 25 percent of issued shares. The filing also shows no outstanding share option schemes, warrants, convertible securities, or other equity-linked instruments that could dilute current shareholders.\nThe return was submitted by Chairman and CEO Ma Zhenkun, reaffirming the stability of the biopharmaceutical company’s capital base heading into the final quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}